|Day Low/High||123.20 / 124.33|
|52 Wk Low/High||92.98 / 137.54|
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,950 million for the first quarter of 2017, an 18 percent increase from the same period in 2016.
U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.
Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.
True driving force behind this market remains earnings, says Jim Cramer, but don't ignore the impact of tax reform -- if it happens.
I prefer a very short-term, out-of-the-money vertical call spread expiring in May.
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Doug Kass shares his thoughts on Apple, Allergan and Western Digital.
Some recent high-flying biotechs may be preparing for their next surge.
Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.
These stocks should be part of a strong first-quarter earnings season.
Celgene Corporation (NASDAQ:CELG) has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc.
Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 27, 2017 at 9 a.
The amazing first quarter didn't rely just on Trump.
Jim Cramer ponders how Breen is getting it done for DuPont, and discusses why the markets love seniors so gosh darn much.
Jim Cramer is bullish on Halliburton, Schlumberger, Cypress Semiconductor and Celgene
Tech's organic growth and visibility has been apparent all year, says Jim Cramer.
The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.
Doug Kass shares his thoughts on Twitter and talks about Sears.
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.
Strong biotech stock has surged since November and is close to all-time highs.
Investor sentiment soured on Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.
Stocks are slightly lower by early afternoon Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.
Early morning gains quickly evaporate on Thursday as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.